Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
During the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as N-1- and N-2-(5-methyl-2-oxo-1,3-dioxolen-4-y...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/20/12/19762 |
id |
doaj-597524469ce24822a97c25c3abeac4a0 |
---|---|
record_format |
Article |
spelling |
doaj-597524469ce24822a97c25c3abeac4a02020-11-24T22:56:06ZengMDPI AGMolecules1420-30492015-12-012012213462136310.3390/molecules201219762molecules201219762Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?Iwona Dams0Anna Ostaszewska1Maria Puchalska2Justyna Chmiel3Piotr Cmoch4Iwona Bujak5Agata Białońska6Wojciech J. Szczepek7Pharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandFaculty of Chemistry, University of Wrocław, Joliot-Curie 14, 50-383 Wrocław, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandDuring the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as N-1- and N-2-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl derivatives of OM. Both compounds, of which N-2 isomer of olmesartan dimedoxomil is a novel impurity of OM, were synthesized and fully characterized by differential scanning calorimetry (DSC), infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR) and high-resolution mass spectrometry/electrospray ionization (HRMS/ESI). Their 1H, 13C and 15N nuclear magnetic resonance signals were fully assigned. The molecular structures of N-triphenylmethylolmesartan ethyl (N-tritylolmesartan ethyl) and N-tritylolmesartan medoxomil, the key intermediates in OM synthesis, were solved and refined using single-crystal X-ray diffraction (SCXRD). The SCXRD study revealed that N-tritylated intermediates of OM exist exclusively as one of the two possible regioisomers. In molecular structures of these regioisomers, the trityl substituent is attached to the N-2 nitrogen atom of the tetrazole ring, and not to the N-1 nitrogen, as has been widely reported up to the present. This finding indicates that the reported structural formula of N-tritylolmesartan ethyl and N-tritylolmesartan medoxomil, as well as their systematic chemical names, must be revised. The careful analysis of literature spectroscopic data for other sartan intermediates and their analogs with 5-(biphenyl-2-yl)tetrazole moiety showed that they also exist exclusively as N-2-trityl regioisomers.http://www.mdpi.com/1420-3049/20/12/19762crystal structureimpuritiesmedoxomilNMR spectroscopyolmesartanprodrugsregioisomerssartansstructuresynthesis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Iwona Dams Anna Ostaszewska Maria Puchalska Justyna Chmiel Piotr Cmoch Iwona Bujak Agata Białońska Wojciech J. Szczepek |
spellingShingle |
Iwona Dams Anna Ostaszewska Maria Puchalska Justyna Chmiel Piotr Cmoch Iwona Bujak Agata Białońska Wojciech J. Szczepek Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist? Molecules crystal structure impurities medoxomil NMR spectroscopy olmesartan prodrugs regioisomers sartans structure synthesis |
author_facet |
Iwona Dams Anna Ostaszewska Maria Puchalska Justyna Chmiel Piotr Cmoch Iwona Bujak Agata Białońska Wojciech J. Szczepek |
author_sort |
Iwona Dams |
title |
Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist? |
title_short |
Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist? |
title_full |
Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist? |
title_fullStr |
Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist? |
title_full_unstemmed |
Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist? |
title_sort |
synthesis and physicochemical characterization of the process-related impurities of olmesartan medoxomil. do 5-(biphenyl-2-yl)-1-triphenylmethyltetrazole intermediates in sartan syntheses exist? |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2015-12-01 |
description |
During the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as N-1- and N-2-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl derivatives of OM. Both compounds, of which N-2 isomer of olmesartan dimedoxomil is a novel impurity of OM, were synthesized and fully characterized by differential scanning calorimetry (DSC), infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR) and high-resolution mass spectrometry/electrospray ionization (HRMS/ESI). Their 1H, 13C and 15N nuclear magnetic resonance signals were fully assigned. The molecular structures of N-triphenylmethylolmesartan ethyl (N-tritylolmesartan ethyl) and N-tritylolmesartan medoxomil, the key intermediates in OM synthesis, were solved and refined using single-crystal X-ray diffraction (SCXRD). The SCXRD study revealed that N-tritylated intermediates of OM exist exclusively as one of the two possible regioisomers. In molecular structures of these regioisomers, the trityl substituent is attached to the N-2 nitrogen atom of the tetrazole ring, and not to the N-1 nitrogen, as has been widely reported up to the present. This finding indicates that the reported structural formula of N-tritylolmesartan ethyl and N-tritylolmesartan medoxomil, as well as their systematic chemical names, must be revised. The careful analysis of literature spectroscopic data for other sartan intermediates and their analogs with 5-(biphenyl-2-yl)tetrazole moiety showed that they also exist exclusively as N-2-trityl regioisomers. |
topic |
crystal structure impurities medoxomil NMR spectroscopy olmesartan prodrugs regioisomers sartans structure synthesis |
url |
http://www.mdpi.com/1420-3049/20/12/19762 |
work_keys_str_mv |
AT iwonadams synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist AT annaostaszewska synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist AT mariapuchalska synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist AT justynachmiel synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist AT piotrcmoch synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist AT iwonabujak synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist AT agatabiałonska synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist AT wojciechjszczepek synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist |
_version_ |
1725654935505207296 |